Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway

Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway

Background: Lcz696 (ARNI, angiotensin receptor–neprilysin inhibitor; sacubitril/valsartan) shows an inhibitory effect on fibrosis after myocardial infarction (MI). However, the underlying signaling mechanisms are poorly understood. The Wnt/β-catenin signaling pathway is activated after MI and partic...

Full description

Bibliographic Details
Main Authors: Jing Liu, Xuehui Zheng, Chen Zhang, Chunmei Zhang, Peili Bu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Pharmacology
Subjects:
myocardial infarction
myocardial fibrosis
LCZ696
Wnt/β-catenin signaling
SFRP-1
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.724147/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.724147/full

Similar Items